ClinicalTrials.gg
RecruitingNCT06411964Updated May 16, 2024

Galactooligosaccharide and Aging

An interventional study of Prebiotic and Placebo control in Muscle Loss, sponsored by University of Bath. Recruiting at 1 site in United Kingdom. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by University of Bath · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Muscular Atrophy with a site in United Kingdom — 7 open to participants now, 11 under way, 2 of them phase 3. Muscular Atrophy · United Kingdom.

Planned enrollment
21st of 42
30 · median 30
Started
2024
the only one that year
No phase
30 of 52
6 open now
Primary completion
2025-10
later than 1 of 10 live
Registered
47th of 52
by date
Lead sponsor
3 of 52
University of Bath

Among the 52 studies in Muscular Atrophy with a site in United Kingdom, this one is the 21st largest by planned enrollment of the 42 interventional ones that give a count, is the only one that started in 2024, is one of 30 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 47th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

7 of the 52 studies in Muscular Atrophy with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 65 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Muscular Atrophy with a site in United Kingdom, or all of them as a file.
02

Study summary

Sarcopenia is a progressive muscle disease, most commonly affecting older individuals, that is categorised by 1) low muscle strength, 2) low muscle quantity or quality, and 3) low physical performance. This disease has several negative implications for human health, including an increased risk of falls, fractures, mobility limitations, and mortality. Sarcopenia also imposes significant burden on healthcare systems. For example, it was estimated that a 10% reduction in the prevalence of sarcopenia would save the US healthcare system $1.1 billion per year. Strategies to reduce the incidence and severity of sarcopenia are therefore of great interest.

One potential cause for sarcopenia is long-term, low-level inflammation, which can occur for a number of reasons. One cause may relate to the intestinal wall becoming more susceptible to leaking of toxic particles. Evidence suggests that prebiotic supplementation can reduce this 'leakage'. Galactooligosaccharide (a prebiotic) has previously been shown to reduce inflammation in elderly individuals. The investigators hypothesise that galactooligosaccharide will improve physical function in the elderly indirectly via a reduction in inflammation.

This will be a randomised, placebo-controlled, double-blind, parallel study. 32 elderly individuals (65-85 years; mix of males and females) will be randomised to one of two groups, GOS or PLACEBO. The GOS group will supplement their diet with 2.9 g galactooligosaccharide per day for 16 weeks in the form of one sachet (3.65 g) of Bimuno® Daily.

The PLACEBO group will supplement with 3.65 g maltodextrin per day for 16 weeks. The study will involve one screening visit and two main trials (baseline and 16 weeks). For the main trials, participants will complete the short physical performance battery (SPPB) and handgrip strength test. In addition, participants will provide blood, urine and faecal samples, as well as a dual-energy x-ray absorptiometry (DEXA), and a peripheral quantitative computed tomography (pQCT) scan.

03

Conditions studied

  • Muscle Loss

Keywords

  • sarcopenia
  • physical function
  • aging
  • gut microbiome
  • prebiotic
04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 65-85 years
  • Able to rise from a chair without using arms

Exclusion criteria

Exclusion Criteria:

  • Use of products marketed as prebiotics, probiotics or synbiotics within 4 weeks prior to study entry (e.g., Yakult, Actimel, Activia, VSL#3, Kefir). Regular cheese or yogurt containing lactic acid bacteria are not an exclusion criterion

    • Systemic antibiotic or antimycotic treatment 6 weeks prior to study entry.
    • Following diets likely to affect study outcomes: e.g., low FODMAP, KETO/high-fat, gluten free/coeliac, paleo, weight loss, caloric restriction, low-carb, 5:2/whole day energy restriction, Atkins/high-protein, sugar-free, single-food, juicing/any day of juicing, any other restriction diet (e.g. very low calorie), or vegan diets (GOS is derived from cow's milk)
    • Meeting physical activity guidelines for older adults:
  • Activities that improve strength, flexibility and balance at least two days per week
  • At least 150 minutes of moderate-intensity activity, or 75 minutes of vigorous activity

    • Body mass loss of ≥ 5% in preceding 6 months
    • History of injury or surgery that would affect physical ability to undertake physical tests
    • History of gastrointestinal disease (e.g., inflammatory bowel disease, irritable bowel syndrome)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    GOS

    Galactooligosaccharide (GOS) is a prebiotic supplement. Taken once daily for the duration for the intervention

    Dietary Supplement: Prebiotic

  • Placebo comparator
    Placebo

    Maltodextrin placebo taken once daily for the duration of the intervention

    Dietary Supplement: Placebo control

Interventions

  • Dietary supplementPrebioticsStudies of PrebioticsPrebiotics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Commercially available supplement (Bimuno)

  • Dietary supplementPlacebo control

    maltodextrin control supplement

06

What researchers measure

Primary outcomes

  1. Mid-thigh muscle cross sectional area

    pQCT assessment of mid-thigh cross sectional area

    Time frame: 16 weeks

Secondary outcomes

  1. Short performance physical battery

    composite test of balance, gait speed and chair stand tests where performance on each three tests scores of maximum of 4 points, combined to score a maximum of 12 points

    Time frame: 16 weeks

  2. Handgrip strength

    dominant and non-dominant hand scores

    Time frame: 16 weeks

  3. appendicular lean mass/height^2 (kilograms/metres^2)

    assessed via DEXA scan

    Time frame: 16 weeks

  4. gait speed

    4m gait speed at usual walking pace (metres/second)

    Time frame: 16 weeks

  5. chair stand

    5 time chair stand (seconds)

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
  • University of Bath
    Bath, Bath And NE Somerset BA2 7AY, United Kingdom
    Recruiting
    • Adam Collins · Contactac3413@bath.ac.uk · 07710611694
    • Adam Collins Collins, MSc · Principal investigator
    • Javier Gonzalez, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Oct 2025, 17 months after the start.

Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 17 months is below that.

Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
May 14, 2024
StartActual
May 2, 2024
Primary completionEst.
Oct 6, 2025
CompletionEst.
Oct 6, 2025
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06411964
Lead sponsor
University of Bath
Responsible party
Adam Collins (Principal Investigator, University of Bath) — Principal investigator
First posted
May 14, 2024
Start date
May 2, 2024
Primary completion
Oct 6, 2025 (estimated)
Completion
Oct 6, 2025 (estimated)
Last update
May 16, 2024

Study contacts

Adam J Collins
Contact
ac3413@bath.ac.uk
07710611694
Javier T Gonzalez
Contact
jg833@bath.ac.uk
01225385518

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prebiotics

Start the discussion